Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


Purpose. The purpose was to examine characteristics, treatment and outcome in an unselected, prospectively registered complete population of patients with gastro-oesophageal adenocarcinoma cancer (GEA). Methods. All cases diagnosed with GEA between 2008 and 2009 in the Region of Southern Denmark (pop: 1 200 000) were registered. Patient characteristics, including performance status, stage and therapy, were retrieved from patient charts and used to compare sub-groups of patients. Results. Three hundred and thirty patients were registered as having GEA. Patients were divided into three clinical subgroups based on initial treatment option: group 1: patients with resectable GEA (n = 113); group 2: patients receiving first-line therapy (n = 107); group 3: patients receiving no tumour-directed therapy (n = 110). Median overall survival (95% CI) in the three groups was 36 months (25-not reached), 7.1 months (7-9) and 2.4 months (2-3), respectively. Seven percent of patients participated in clinical trials. Conclusion. Among patients not amendable to resection, around 30% are candidates for three-drug combination chemotherapy. Age > 65 years was found not to be a poor prognostic factor for survival, giving the possibility of treating elderly patients in the future. Many patients (approx. 30%), however, never received cancer-directed therapy. In order to improve survival in the entire population, it is important that future trials also focus on this group of patients.
TidsskriftActa Oncologica
Udgave nummer3
Sider (fra-til)385-391
StatusUdgivet - 2014

Bibliografisk note

ISI Document Delivery No.: AB5BP Times Cited: 0 Cited Reference Count: 24 Schonnemann, Katrine R. Mortensen, Michael B. Bjerregaard, Jon K. Fristrup, Claus Pfeiffer, Per Danish Cancer Society This study was supported by a grant from the Danish Cancer Society. 0 INFORMA HEALTHCARE LONDON ACTA ONCOL